The growing burden of liver cirrhosis: implications for preventive measures Martin C. S. WongJunjie Huang Editorial 20 April 2018 Pages: 201 - 203
Beyond KCH selection and options in acute liver failure William BernalRoger Williams Review Article Open access 01 June 2018 Pages: 204 - 213
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy Ameer AbutalebShyam KottililEleanor Wilson Review Article 29 May 2018 Pages: 214 - 222
Immune checkpoint receptors: homeostatic regulators of immunity Antonio RivaShilpa Chokshi Review Article Open access 08 May 2018 Pages: 223 - 236
Platelets’ increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis Lin WangBingqiong WangJidong Jia Original Article 26 April 2018 Pages: 237 - 243
Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan Fumitaka SuzukiNaoya HatanakaAkira Komoto Original Article 09 June 2018 Pages: 244 - 253
Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation Tetsuyuki TakahashiUlrich DeuschleKoichi Tsuneyama Original Article 12 April 2018 Pages: 254 - 261
Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure Nan ChenXiaohong ChenJie Teng Original Article 28 April 2018 Pages: 262 - 268
Liver cirrhosis and cancer: comparison of mortality Wankyo ChungChangik JoDong Joon Kim Original Article 01 March 2018 Pages: 269 - 276
Plasma miRNA-122-5p and miRNA-151a-3p identified as potential biomarkers for liver injury among CHB patients with PNALT Jin-Lin ChengHong ZhaoLan-Juan Li Original Article 07 June 2018 Pages: 277 - 287
Correction to: Abstracts of the 27th Annual Conference of APASL, March 14–18, 2018, New Delhi, India Correction 23 May 2018 Pages: 288 - 288
Correction to: Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B Tianyu HeYuqing BaiJidong Jia Correction 11 June 2018 Pages: 289 - 289
